Axbio

Axbio Biotechnology, established in 2016, has gathered a team of experts comprising multiple Silicon Valley serial entrepreneurs, multinational corporation executives, senior engineers, and scientists. The company conducts research and development on cutting-edge technologies such as chip development, nanotechnology, microfluidics, biotechnology, bioinformatics, big data, and artificial intelligence in the United States, China, and Europe. It is committed to the development and promotion of high-throughput nanopore single-molecule long-read gene sequencing solutions based on its proprietary microfluidic Bio-CMOS chips, which feature extremely high accessibility, cost-effectiveness, and ultra-high accuracy. After dedicated research efforts, Axbio successfully developed a microfluidic Bio-CMOS platform capable of high-throughput sequencing and molecular diagnostics, making it possible to produce low-cost handheld devices for point-of-care and consumer use as well as fully automated instruments for independent laboratories and hospitals. This marks the world's first truly low-cost, long-read, easy-to-use fourth-generation gene sequencer. Axbio's innovative capabilities have continuously drawn attention and investment from top global venture capital firms.